- Home
- VOR
as 11-07-2025 3:53pm EST
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 207.1M | IPO Year: | 2021 |
| Target Price: | $84.00 | AVG Volume (30 days): | 385.7K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -342.66 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.62 - $65.80 | Next Earning Date: | 11-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Vor Biopharma Inc. (VOR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | VOR | Director, 10% Owner | Oct 30 '25 | Sell | $25.12 | 24,579 | $617,424.48 | 779,652 | |
| RA CAPITAL MANAGEMENT, L.P. | VOR | Director, 10% Owner | Oct 29 '25 | Sell | $25.22 | 251,518 | $6,343,283.96 | 779,652 | |
| RA CAPITAL MANAGEMENT, L.P. | VOR | Director, 10% Owner | Oct 28 '25 | Sell | $27.64 | 124,311 | $3,408,229.74 | 779,652 | |
| RA CAPITAL MANAGEMENT, L.P. | VOR | Director, 10% Owner | Oct 27 '25 | Sell | $28.12 | 90,941 | $2,557,260.92 | 779,652 | |
| RA CAPITAL MANAGEMENT, L.P. | VOR | Director, 10% Owner | Oct 24 '25 | Sell | $28.01 | 53,345 | $1,494,193.45 | 779,652 | |
| RA CAPITAL MANAGEMENT, L.P. | VOR | Director, 10% Owner | Oct 23 '25 | Sell | $28.01 | 76,880 | $2,153,408.80 | 779,652 | |
| RA CAPITAL MANAGEMENT, L.P. | VOR | Director, 10% Owner | Oct 21 '25 | Sell | $28.11 | 25,027 | $703,508.97 | 779,652 | |
| Reprogrammed Interchange LLC | VOR | 10% Owner | Oct 21 '25 | Sell | $30.08 | 200 | $6,015.00 | 1,166,909 | |
| RA CAPITAL MANAGEMENT, L.P. | VOR | Director, 10% Owner | Oct 20 '25 | Sell | $29.88 | 92,023 | $2,730,483.09 | 779,652 | |
| Reprogrammed Interchange LLC | VOR | 10% Owner | Oct 20 '25 | Sell | $30.05 | 11,616 | $349,101.46 | 1,166,909 |
Latest Vor Biopharma Inc. News
VOR Breaking Stock News: Dive into VOR Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer
GlobeNewswire
8 days ago
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
10 days ago
Vor Biopharma Says Telitacicept Sustains Efficacy in Phase 3 Myasthenia Gravis Trial in China
GlobeNewswire
17 days ago
Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease
Argus Research
17 days ago
Daily – Vickers Top Buyers & Sellers for 10/22/2025
Argus Research
19 days ago
Daily – Vickers Top Buyers & Sellers for 10/20/2025
TipRanks
22 days ago
Vor Bio announces Phase 3 study on telitacicept in SLE met primary endpoint
GlobeNewswire
22 days ago
Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025
Compare VOR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VOR Vor Biopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.